NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $22.56 +0.01 (+0.04%) Closing price 04:00 PM EasternExtended Trading$22.44 -0.12 (-0.53%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$22.47▼$22.8350-Day Range$17.16▼$22.9552-Week Range$13.40▼$25.23Volume1.52 million shsAverage Volume1.97 million shsMarket Capitalization$3.78 billionP/E Ratio16.47Dividend YieldN/APrice Target$27.88Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California, focused on the discovery, development and commercialization of innovative therapies for central nervous system (CNS) disorders. Since its founding in 1993, the company has concentrated on small molecule drug candidates designed to address neuropsychiatric and neurological conditions that have significant unmet medical needs. The company’s flagship product is pimavanserin, marketed under the brand name NUPLAZID, which received U.S. Food and Drug Administration approval as the first and only therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Pimavanserin is also being evaluated in clinical trials for additional indications, including dementia-related psychosis, Alzheimer’s disease psychosis and major depressive disorder. Through strategic partnerships and licensing agreements, ACADIA has established a presence in key markets across North America, Europe and Asia to advance its development programs and broaden patient access. ACADIA is led by President and Chief Executive Officer Stephen R. Davis, one of the company’s co-founders, and supported by a leadership team with deep expertise in neuroscience research and drug development. The company maintains research and development operations in San Diego and collaborates with academic institutions and industry partners worldwide. With a robust pipeline of CNS-focused candidates and a demonstrated track record in commercial execution, ACADIA aims to deliver new treatment options that improve the quality of life for patients living with challenging neuropsychiatric disorders.AI Generated. May Contain Errors. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 221st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 10 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.57% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 8.57% in the coming year, from $0.70 to $0.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 16.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.51.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 16.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.06.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 4.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.43% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 16.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.43% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 16.90%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.57 News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for ACADIA Pharmaceuticals this week, compared to 9 articles on an average week.Search InterestOnly 4 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows7 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $525,079.00 in company stock.Percentage Held by Insiders26.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesHigh Growth Tech Stocks In The US For July 2025July 18 at 3:45 PM | finance.yahoo.comResearch Analysts Set Expectations for ACAD Q4 EarningsJuly 14, 2025 | americanbankingnews.comMiss This Window And You Miss EverythingThere’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the phase when momentum builds, news turns bullish, and markets ignite. Inside The Crypto Code Workshop, you’ll get the roadmap to ride this wave — and $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Acadia Emerges From Behind The Scenes With A Potential $12 Billion OpportunityJuly 11, 2025 | msn.comACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid pipeline expansionJuly 8, 2025 | investing.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | businesswire.comAnalysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Roivant Sciences (ROIV) and Walgreens Boots Alliance (WBA)July 2, 2025 | theglobeandmail.comStocks Showing Improving Market Leadership: Ionis Pharmaceuticals Earns 84 RS RatingJuly 2, 2025 | msn.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $18.35 at the beginning of the year. Since then, ACAD stock has increased by 23.1% and is now trading at $22.58. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Wednesday, May, 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals's revenue was up 18.7% on a year-over-year basis. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (1.02%), Wesbanco Bank Inc. (0.05%), State of Alaska Department of Revenue (0.04%) and Truist Financial Corp (0.02%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Mark C Schneyer, Brendan Teehan, Srdjan R Stankovic, Austin D Kim, James Kihara, Elizabeth A Garofalo and Laura Brege. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings5/07/2025Today7/18/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year FoundedN/APrice Target and Rating Average Price Target for ACADIA Pharmaceuticals$27.88 High Price Target$38.00 Low Price Target$20.00 Potential Upside/Downside+22.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$1.37 Trailing P/E Ratio16.56 Forward P/E Ratio32.44 P/E Growth4.86Net Income$226.45 million Net Margins22.97% Pretax Margin26.58% Return on Equity17.46% Return on Assets10.75% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.80 Sales & Book Value Annual Sales$957.80 million Price / Sales3.97 Cash Flow$0.71 per share Price / Cash Flow31.99 Book Value$4.40 per share Price / Book5.16Miscellaneous Outstanding Shares167,360,000Free Float123,011,000Market Cap$3.80 billion OptionableOptionable Beta0.64 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ACAD) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.